Bortezomib Reinduction Chemotherapy in High-Risk ALL in First Relapse: A Report from the Children’s Oncology Group

While survival in paediatric acute lymphoblastic leukaemia (ALL) is excellent, survival following relapse is poor. Previous studies suggest proteasome inhibition with chemotherapy improves relapse ALL response rates. This phase 2 Children’s Oncology Group study tested the hypothesis that adding the...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Br J Haematol
Autores principales: Horton, Terzah M., Whitlock, James A., Lu, Xiaomin, O’Brien, Maureen M., Borowitz, Michael J., Devidas, Meenakshi, Raetz, Elizabeth A., Brown, Patrick A., Carroll, William L., Hunger, Stephen P.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2019
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6606340/
https://ncbi.nlm.nih.gov/pubmed/30957229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15919
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares